Anavex Life Sciences Corp. (NASDAQ:AVXL) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $12.50 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also given Anavex Life Sciences Corp. an industry rank of 92 out of 265 based on the ratings given to its competitors.

Several analysts have weighed in on AVXL shares. Maxim Group reiterated a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, FBR & Co reiterated an “outperform” rating and set a $10.00 price target on shares of Anavex Life Sciences Corp. in a research note on Tuesday, July 26th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/anavex-life-sciences-corp-nasdaqavxl-given-12-50-average-target-price-by-analysts.html

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 1.54% during mid-day trading on Tuesday, hitting $2.64. The company had a trading volume of 522,028 shares. The company has a 50-day moving average price of $3.10 and a 200 day moving average price of $4.64. Anavex Life Sciences Corp. has a 12 month low of $2.45 and a 12 month high of $14.84. The firm’s market capitalization is $94.27 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Equities analysts forecast that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Rhumbline Advisers bought a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $192,000. Teachers Advisors Inc. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $314,000. American International Group Inc. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $115,000. BlackRock Institutional Trust Company N.A. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $1,739,000. Finally, BlackRock Fund Advisors boosted its position in shares of Anavex Life Sciences Corp. by 15,563.2% in the second quarter. BlackRock Fund Advisors now owns 849,417 shares of the company’s stock valued at $5,190,000 after buying an additional 843,994 shares during the period. 10.72% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

5 Day Chart for NASDAQ:AVXL

Get a free copy of the Zacks research report on Anavex Life Sciences Corp. (AVXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.